Targeted Therapeutic Conjugates for Selective Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic and anti-infective agents lack tissue selectivity, leading to adverse effects on non-cancerous and non-infected tissues due to their non-specific distribution, necessitating the development of targeted therapeutic approaches for cancer and infection treatment.
Innovation Solution
The development of conjugates comprising a recognition element covalently bonded to a payload through a linker, where the recognition element is recognizable by specific microorganisms or proteins, allowing for targeted delivery of antineoplastic or anti-infective agents to cancerous or infected sites, such as colorectal cancer tissues, by utilizing enzymes produced by bacteria like E. coli or Klebsiella pneumoniae for cleavage and release of the payload.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are administered to treat cancer, then the therapeutic effect on cancerous tissue is improved, but the agents affect non-cancerous tissue causing side effects
Solution Approach 1:
The therapeutic agent is segmented into a conjugate system consisting of three distinct components: a recognition element (bacterial enzyme substrate), a linker, and a payload (therapeutic agent). This segmentation allows the payload to be delivered specifically to sites where the recognition element can be cleaved by bacterial enzymes, separating the therapeutic action from healthy tissues that lack these enzymes.
Solution Approach 2:
A linker acts as an intermediary between the recognition element and the payload. The linker is designed to be cleaved specifically by bacterial enzymes (such as beta-lactamases, beta-glucuronidases, or sulfatases) that are overexpressed at the disease site. This intermediary mechanism enables selective activation of the payload only in the presence of the target bacterial enzymes, protecting healthy tissues from exposure.
2Reliability
If anti-infective agents are dosed at levels sufficient to treat infection, then the therapeutic effect on infected tissue is improved, but the agents affect host cells and tissues causing toxicities
Solution Approach 1:
The anti-infective therapy is segmented into a conjugate where the anti-infective payload is attached to a recognition element. This segmentation allows the conjugate to be administered systemically without immediately exposing host cells to high doses of the anti-infective agent. The payload is only released at the infection site where bacterial enzymes cleave the linker, achieving high local concentration while maintaining low systemic exposure and reducing host cell toxicity.
Solution Approach 2:
The linker serves as an intermediary that protects the host from direct exposure to high doses of anti-infective agents. The linker is designed to be stable in normal physiological conditions but is specifically cleaved by bacterial enzymes at the infection site. This intermediary mechanism enables the delivery of therapeutic doses to the infection site while avoiding toxic effects on host cells and tissues.
3Ease of operation
If conventional therapeutic agents are used, then the treatment can be administered systemically, but the distribution is non-specific affecting both diseased and healthy tissues
Solution Approach 1:
The therapeutic conjugate is segmented into a recognition element specifically designed to interact with bacterial enzymes and a payload. This segmentation enables the conjugate to be administered systemically like conventional therapies, but the recognition element guides the payload specifically to sites infected with bacteria that produce the target enzymes, achieving precise tissue distribution selectivity.
Solution Approach 2:
The conjugate system changes the parameter of tissue distribution selectivity by incorporating a recognition element with specific affinity for bacterial enzymes. The linker is designed with specific cleavage characteristics that change the release kinetics of the payload, ensuring stable circulation systemically but rapid release only at the target site where the corresponding bacterial enzymes are present.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables targeted delivery of therapeutic agents directly to disease sites, reducing adverse effects on healthy tissues and enhancing the efficacy of treatments for cancer and infections by utilizing specific bacterial enzymes for controlled release of the payload.
Implementation Method 1
The linker is cleavable in vivo by an enzyme to release the payload from the conjugate. In some embodiments, the enzyme is produced by a microorganism.
Data Source
AI summary
Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.